Aberrant promoter methylation of CDH13 and MGMT genes is associated with clinicopathologic characteristics of primary non-small-cell lung carcinoma.

abstract：:Combined-modality therapy with chemotherapy and radiation appears to be the most efficacious therapeutic modality for patients with locally advanced non-small-cell lung cancer. Most of the trials exploring this approach have utilized older agents such as cisplatin, vinblastine, and etoposide. Recent data suggest that ...

journal_title：Clinical lung cancer

authors： Curran WJ Jr

更新日期：2002-03-01 00:00:00

abstract：BACKGROUND:The optimal treatment of locally advanced non-small-cell lung cancer (NSCLC) remains controversial. We hypothesized that using a trimodality approach in selected patients with stage IIIA/IIIB disease would be both feasible and efficacious with reasonable toxicity. PATIENTS/METHODS:We enrolled 13 patients wi...

journal_title：Clinical lung cancer

authors： Das M,Donington JS,Murphy J,Kozak M,Eclov N,Whyte RI,Hoang CD,Zhou L,Le QT,Loo BW,Wakelee H

更新日期：2011-09-01 00:00:00

abstract：BACKGROUND:The level of N-terminal pro-B-type natriuretic peptide (NT-proBNP) is affected by many known factors. Our study aimed to evaluate whether other factors, in particular lung cancer, could be responsible for an increase in NT-proBNP levels in a population with no known risk factors for elevated NT-proBNP. PATI...

journal_title：Clinical lung cancer

authors： Aujollet N,Meyer M,Cailliod R,Combier F,Coignet Y,Campard S,Facy O,Bernard A,Girard C

更新日期：2010-09-01 00:00:00

abstract：INTRODUCTION:Malignant pleural mesothelioma (MPM) is a devastating neoplasm; however, some patients exhibit a good response to chemotherapy or multidisciplinary therapy, including surgery and chemotherapy. It is therefore important to discover the factors that can be used to select patients who will benefit from such t...

journal_title：Clinical lung cancer

authors： Takamori S,Toyokawa G,Taguchi K,Edagawa M,Shimamatsu S,Toyozawa R,Nosaki K,Seto T,Hirai F,Yamaguchi M,Shoji F,Okamoto T,Takenoyama M,Ichinose Y

更新日期：2017-07-01 00:00:00

abstract：:Current treatments of non-small-cell lung cancer (NSCLC) are inadequate and new therapies are being developed that target specific cellular signaling proteins associated with tumor growth. One potential target is protein kinase C (PKC)-alpha, a signaling molecule with an important role in cell regulation and prolifera...

journal_title：Clinical lung cancer

authors： Lahn M,Su C,Li S,Chedid M,Hanna KR,Graff JR,Sandusky GE,Ma D,Niyikiza C,Sundell KL,John WJ,Giordano TJ,Beer DG,Paterson BM,Su EW,Bumol TF

更新日期：2004-11-01 00:00:00

abstract：:There is a high risk of relapse after curative-intent resection for even early-stage non-small cell lung cancer (NSCLC), and thus adjuvant chemotherapy has been explored with the goal of eliminating occult metastases and consequently reducing the risk of recurrence. Although adjuvant chemotherapy confers a survival ad...

journal_title：Clinical lung cancer

authors： Carbone DP,Felip E

更新日期：2011-09-01 00:00:00

abstract：INTRODUCTION:Clinical manifestation of non-small-cell lung cancer (NSCLC) mainly occurs at advanced stages. Thus, the scientific community is evaluating different screening programs in high-risk patients to detect NSCLC at an earlier stage to improve survival. However, up to now patient selection and modalities have be...

journal_title：Clinical lung cancer

authors： Kocher F,Lunger F,Seeber A,Amann A,Pircher A,Hilbe W,Fiegl M

更新日期：2016-01-01 00:00:00

abstract：INTRODUCTION:Maintenance therapy is a new treatment paradigm for advanced non-small-cell lung cancer (NSCLC). We conducted a meta-analysis to evaluate its clinical efficacy in NSCLC and compared the efficacy of chemotherapy, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), and other treatment ap...

journal_title：Clinical lung cancer

authors： Zhang C,Huang C,Wang J,Wang X,Li K

更新日期：2015-09-01 00:00:00

abstract：BACKGROUND:The purpose of this study was to assess the applicability of an annual low-dose computed tomography (CT) screening program for lung cancer in a single institution in Israel, which has a relatively lower prevalence of lung cancer compared with other Western countries, and to examine stage distribution of dete...

journal_title：Clinical lung cancer

authors： Shaham D,Breuer R,Copel L,Agid R,Makori A,Kisselgoff D,Goitein O,Izhar U,Berkman N,Heching N,Sosna J,Bar-Ziv J,Libson E

更新日期：2006-01-01 00:00:00

abstract：BACKGROUND:In the present study we aimed to investigate whether the predominance of the lepidic component in tumors was associated with the outcome of postoperative adjuvant chemotherapy for stage I lung adenocarcinoma. PATIENTS AND METHODS:Charts for patients with pathological stage I lung adenocarcinoma were retrosp...

journal_title：Clinical lung cancer

authors： Sasada S,Miyata Y,Mimae T,Tsutani Y,Mimura T,Okada M

更新日期：2016-09-01 00:00:00

abstract：OBJECTIVE:The objective of this study is to externally validate the 8th Edition of the Tumor, Node, and Metastasis staging system and its updated T descriptors in patients with non-small cell lung cancer with N3 disease. METHODS:Data were extracted from the Surveillance, Epidemiology, and End Results database. Chi-squ...

journal_title：Clinical lung cancer

authors： Shin JY,Yoon JK,Marwaha G

更新日期：2017-11-01 00:00:00

abstract：BACKGROUND:A few reports have evaluated the outcomes of concurrent chemoradiotherapy (CRT) for patients with postoperative recurrence of non-small cell lung cancer (NSCLC). PATIENTS AND METHODS:From 2000 through 2011, 1237 consecutive patients with NSCLC underwent pulmonary resection at our institution. Of those, 280 ...

journal_title：Clinical lung cancer

authors： Takenaka T,Takenoyama M,Toyozawa R,Inamasu E,Yoshida T,Toyokawa G,Shiraishi Y,Hirai F,Yamaguchi M,Seto T,Ichinose Y

更新日期：2015-01-01 00:00:00

abstract：INTRODUCTION:Frailty of surgical patients has been associated with worse outcomes. There is limited literature discussing frailty in patients with lung cancer treated with stereotactic body radiotherapy (SBRT). This study assesses the relationship between frailty and overall survival (OS), tumor control, and toxicity i...

journal_title：Clinical lung cancer

authors： Raghavan G,Shaverdian N,Chan S,Chu FI,Lee P

更新日期：2018-09-01 00:00:00

abstract：BACKGROUND:Patients with multiple primary lung cancers increasingly receive multiple courses of stereotactic body radiotherapy (SBRT). We aimed to clarify the efficacy and safety of such treatments. PATIENTS AND METHODS:We reviewed a prospective lung SBRT database of patients treated for stage I non-small-cell lung ca...

journal_title：Clinical lung cancer

authors： Nikitas J,DeWees T,Rehman S,Abraham C,Bradley J,Robinson C,Roach M

更新日期：2019-03-01 00:00:00

abstract：BACKGROUND:Major guidelines do not recommend routine molecular profiling of lung squamous-cell carcinoma (LUSC) because the prevalence of actionable alterations is thought to be low. Increased utilization of next-generation sequencing (NGS), particularly with cell-free circulating tumor DNA, facilitates reevaluation of...

journal_title：Clinical lung cancer

authors： Lam VK,Tran HT,Banks KC,Lanman RB,Rinsurongkawong W,Peled N,Lewis J,Lee JJ,Roth J,Roarty EB,Swisher S,Talasaz A,Futreal PA,Papadimitrakopoulou V,Heymach JV,Zhang J

更新日期：2019-01-01 00:00:00

abstract：:Lung cancer is the leading cause of cancer deaths worldwide, with the majority of patients presenting with advanced disease. Despite the introduction of newer therapeutic agents and modest survival improvement, the overall prognosis for these patients is poor. The goals of therapy should therefore include improvement ...

journal_title：Clinical lung cancer

authors： Plunkett TA,Chrystal KF,Harper PG

更新日期：2003-07-01 00:00:00

abstract：BACKGROUND:The programmed death 1/programmed death-ligand 1 (PD-L1) pathway reportedly is as an important factor determining effects of immunotherapy; however, its prognostic impact is controversial, and its association with the surrounding immune microenvironment has not yet been elucidated. PATIENTS AND METHODS:We r...

journal_title：Clinical lung cancer

authors： Handa Y,Tsutani Y,Shiroma N,Kai Y,Mimae T,Miyata Y,Takeshima Y,Arihiro K,Okada M

更新日期：2020-07-01 00:00:00

abstract：INTRODUCTION:We set out to investigate whether volumetric tumor measurements allow for a prediction of treatment response, as measured by patient survival, in patients with advanced non-small-cell lung cancer (NSCLC). MATERIALS AND METHODS:Patients with nonresectable NSCLC (stage III or IV, n = 100) who were repeatedl...

journal_title：Clinical lung cancer

authors： Knollmann FD,Kumthekar R,Fetzer D,Socinski MA

更新日期：2014-03-01 00:00:00

abstract：BACKGROUND:We investigated the effect of downstaging on OS in LD-SCLC patients treated with first-line treatment. PATIENTS AND METHODS:We retrospectively reviewed 210 LD-SCLC patients who were treated with first-line treatment at Seoul National University Hospital between April 1999 and November 2012. Compared with in...

journal_title：Clinical lung cancer

authors： Go SI,Keam B,Kim TM,Lee SH,Kim DW,Kim HJ,Wu HG,Chung DH,Heo DS

更新日期：2014-03-01 00:00:00

abstract：:Small-cell lung cancer (SCLC) is distinguished from non-small-cell lung cancer by its rapid growth and more frequent metastases. Although patients with SCLC are highly responsive to chemotherapy and radiation therapy, long-term prognosis remains poor, with relapse and disease recurrence occurring in almost all cases. ...

journal_title：Clinical lung cancer

authors： Chae YK,Pan A,Davis AA,Mohindra N,Matsangou M,Villaflor V,Giles F

更新日期：2017-03-01 00:00:00

abstract：BACKGROUND:Hormesis is a favorable biological response to low toxin exposure. In the case of radiation, large doses are carcinogenic, but low doses might be protective. In the current study, we analyzed lung cancer incidence in high-impact radiation states where nuclear testing occurred and compared it with lung cancer...

journal_title：Clinical lung cancer

authors： Lehrer S,Rosenzweig KE

更新日期：2015-03-01 00:00:00

abstract：BACKGROUND:The benefits of immune checkpoint inhibitors for first-line treatment in patients with lung adenocarcinoma harboring EGFR mutations are unclear. The effects of ICIs depend on the tumor microenvironment (TME). Differences in TME properties between mutant and wild-type EGFR have not been fully characterized. ...

journal_title：Clinical lung cancer

authors： Gong Z,Chen J,Cheng JN,Sun C,Jia Q,Diao X,Zhu B

更新日期：2018-09-01 00:00:00

abstract：:Viruses capable of inducing lysis of malignant cells through their replication process are known as "oncolytic" viruses. Clinical trials in oncology have been performed with oncolytic viruses for nearly fifty years. Both systemic and intratumoral routes of administration have been explored. Toxicity has generally been...

journal_title：Clinical lung cancer

authors： Nemunaitis JJ

更新日期：1999-08-01 00:00:00

abstract：INTRODUCTION:Lung cancer is the leading cause of cancer-related death. Many patients with lung cancer are in its advanced stages at the time of diagnosis. The 5-year survival rate for lung cancer is 10% to 20%, and the prognosis for patients with lung cancer is still poor. The crosslinked N-terminal telopeptide of type...

journal_title：Clinical lung cancer

authors： Tamiya M,Kobayashi M,Morimura O,Yasue T,Nakasuji T,Satomu M,Kohei O,Takayuki S,Morishita N,Suzuki H,Sasada S,Okamoto N,Hirashima T,Kawase I

更新日期：2013-01-01 00:00:00

abstract：:Active tumor immunotherapy may provide hope for patients with non-small-cell lung cancer (NSCLC) because, in more than 20 years, current therapies have yet to change mortality statistics. Creating an efficacious vaccine involves selection of important tumor antigens and formulation of their immunogenic epitopes into a...

journal_title：Clinical lung cancer

authors： Holt GE,Disis ML

更新日期：2008-02-01 00:00:00

abstract：:Lung cancer remains the number one cause of cancer-based mortality in men and women. The importance of proper lung cancer care outside of major academic centers cannot be overemphasized because the vast majority of lung cancer care occurs in community hospital settings. We have had the opportunity to develop a highly ...

journal_title：Clinical lung cancer

authors： Fischel RJ,Dillman RO

更新日期：2009-07-01 00:00:00

abstract：BACKGROUND:Several studies have assessed the expression of programmed death-ligand 1 (PD-L1) in resected surgical specimens of non-small-cell lung cancer (NSCLC). However, the expression of PD-L1 in smaller biopsy samples of advanced NSCLC has not been reported. PATIENTS AND METHODS:A total of 79 patients with NSCLC a...

journal_title：Clinical lung cancer

authors： Kitazono S,Fujiwara Y,Tsuta K,Utsumi H,Kanda S,Horinouchi H,Nokihara H,Yamamoto N,Sasada S,Watanabe S,Asamura H,Tamura T,Ohe Y

更新日期：2015-09-01 00:00:00

abstract：OBJECTIVE:Uncertainty exists regarding the optimal surveillance imaging schedule following definitive chemoradiation (CRT) for locally advanced non-small-cell lung cancer (LA-NSCLC) with regards to both frequency and modality. We sought to document the clinical impact of frequent (at least every 4 months) surveillance ...

journal_title：Clinical lung cancer

authors： Ho QA,Harandi NK,Daly ME

更新日期：2017-07-01 00:00:00

abstract：BACKGROUND:First-line treatment of non-small-cell lung cancer (NSCLC) has undergone a paradigm shift to platinum combination therapy together with an immune checkpoint inhibitor (ICI). Bevacizumab is expected to enhance not only chemotherapy but also the efficacy of ICIs through blockade of vascular endothelial growth ...

journal_title：Clinical lung cancer

authors： Shiraishi Y,Kishimoto J,Tanaka K,Sugawara S,Daga H,Hirano K,Azuma K,Hataji O,Hayashi H,Tachihara M,Mitsudomi T,Seto T,Nakagawa K,Yamamoto N,Okamoto I

更新日期：2020-09-01 00:00:00

abstract：BACKGROUND:In advanced epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) patients whose disease has progressed during treatment with first- and second-generation tyrosine kinase inhibitors (TKIs), liquid biopsy (LB) is routinely used to evaluate the presence of EGFR T790M as an acquired...

journal_title：Clinical lung cancer

authors： Minari R,Mazzaschi G,Bordi P,Gnetti L,Alberti G,Altimari A,Gruppioni E,Sperandi F,Parisi C,Guaitoli G,Bettelli S,Longo L,Bertolini F,Pagano M,Bonelli C,Tagliavini E,Nicoli D,Ubiali A,Zangrandi A,Trubini S,Proietto

更新日期：2020-09-01 00:00:00